Table 2.
Associations between vascular risk factors at baseline and progression measured by annual change in CDR-SB
| Age and sex-adjusted | ||||
|---|---|---|---|---|
| Beta | 95% CI | p | R2 | |
| Vascular risk factors (VRFs) | ||||
| Hypertension | −0.049 | (−0.617, 0.519) | 0.87 | 0.04 |
| Hypercholesterolemia | 0.262 | (−0.153, 0.676) | 0.22 | 0.05 |
| Diabetes mellitus | 0.128 | (−0.592, 0.848) | 0.73 | 0.04 |
| Overweight (BMI ≥25) | − 0.391 | (− 0.840, 0.059) | 0.09 | 0.04 |
| Smoking (current) | 0.050 | (−0.677, 0.778) | 0.89 | 0.04 |
| ≥ 2 VRFs | 0.121 | (−0.370, 0.612) | 0.63 | 0.03 |
| ≥ 3 VRFs | −0.371 | (−0.889, 0.147) | 0.16 | 0.04 |
| Framingham Stroke Risk Profile, women* | −0.297 | (−2.769, 2.175) | 0.81 | 0.00 |
| Framingham Stroke Risk Profile, men* | 0.930 | (−1.638, 3498) | 0.47 | 0.01 |
| ApoE ε4 carrier | 0.384 | (−0.069, 0.836) | 0.10 | 0.06 |
| Vascular diseases | ||||
| Heart disease | 0.196 | (−0.380, 0.771) | 0.50 | 0.04 |
| Atrial fibrillation | −0.159 | (0.902, 0.583) | 0.67 | 0.04 |
| Peripheral vascular disease | 0.512 | (−0.834, 1.858) | 0.46 | 0.04 |
| Cerebrovascular event (stroke and/or TIA) | −0.315 | (−0.896, 0.265) | 0.29 | 0.04 |
| MRI findings | ||||
| Cortical infarcts (1 = cortical infarcts, 0 = no cortical infarcts) | 0.707 | (−0.518, 1.932) | 0.26 | 0.04 |
| Lacunes (1 = ≥1 lacune on MRI, 0 = no lacunes) | −0.177 | (−0.867, 0.514) | 0.61 | 0.04 |
| Infarcts (cortical and/or lacunes) | 0.038 | (−0.611, 0.687) | 0.91 | 0.03 |
| White matter hyperintensities Fazekas 3 | −0.291 | (−0.872, 0.290) | 0.32 | 0.04 |
| White matter hyperintensities Fazekas 2 or 3 | −0.207 | (−0.776, 0.362) | 0.47 | 0.04 |
| Infarcts and/or WMH Fazekas 3 | −0.079 | (−0.625, 0.468) | 0.78 | 0.03 |
| Infarcts and/or WMH Fazekas 2 or 3 | −0.298 | (−0.872, 0.277) | 0.31 | 0.04 |
| MTA (mean of right and left side) | 0.036 | (−0.262, 0.334) | 0.81 | 0.04 |
* The Framingham Stroke Risk Profiles were not adjusted for age and sex